Denali Therapeutics (DNLI) Assets Average (2018 - 2026)

Denali Therapeutics (DNLI) has 9 years of Assets Average data on file, last reported at $1.2 billion in Q1 2026.

• On a quarterly basis, Assets Average fell 8.87% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 8.87% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, changed 0.36% from the prior year.
• Assets Average for Q1 2026 stood at $1.2 billion, up from $1.1 billion in the prior quarter.
• Over the last five years, Assets Average for DNLI reached as high as $1.5 billion in Q2 2024 and fell as low as $1.1 billion in Q4 2025.
• Historically, Assets Average has averaged $1.3 billion across 5 years, with a median of $1.3 billion in 2025.
• Across the five-year window, Assets Average rose 18.3% in 2024 and retreated 24.85% in 2025, its largest moves.
• Year by year, Assets Average stood at $1.3 billion in 2022, then dropped by 11.06% to $1.2 billion in 2023, then advanced by 18.3% to $1.4 billion in 2024, then retreated by 22.2% to $1.1 billion in 2025, then gained by 9.56% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $1.2 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.